PMID- 35957656
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220813
IS  - 2667-2766 (Electronic)
IS  - 2667-2766 (Linking)
VI  - 7
DP  - 2022 Sep
TI  - Implementation of a model integrating primary and oncology pharmacists' care for 
      patients taking oral anticancer agents (OAA).
PG  - 100163
LID - 10.1016/j.rcsop.2022.100163 [doi]
LID - 100163
AB  - Improvements in chronic myeloid leukemia (CML), chronic lymphocytic leukemia 
      (CLL), and multiple myeloma (MM) treatment options have increased the 5-year 
      survival rates for patients with these hematologic malignancies. In addition to 
      cancer management, these patients may need help to manage multiple chronic 
      conditions (MCC). The overall objective of this study is to examine the impact 
      and implementation of a model that coordinates care between oncology and primary 
      care pharmacists for people taking an oral anti-cancer agent (OAAs) and 
      medications for comorbid chronic conditions. This is a multi-center, prospective, 
      single-arm pilot study that will recruit up to 40 patients from Michigan Medicine 
      and Vanderbilt University Medical Center (VUMC). Eligible participants will be 18 
      years of age or older, prescribed an OAA, have a diagnosis of either CML, CLL or 
      MM, and be diagnosed with and taking medication for at least two specified 
      chronic conditions. The Pharmacists Coordinated Care Oncology Model (PCOM) is a 
      two-month intervention that builds upon current pharmacist clinical 
      responsibilities. Generally, participants will complete a patient-reported 
      outcome measure at 2 and 6 weeks post-OAA initiation that is sent to their 
      oncology pharmacist, and they will also receive a comprehensive medication review 
      at week 4 from a primary care pharmacist for their chronic medications. The 
      pharmacists will communicate about the results via electronic medical record 
      (EMR) and intervene if necessary. The primary endpoints are (1) dose-adjusted OAA 
      proportion of days covered (PDC), and (2) PDC for chronic condition medications. 
      PDCs will be determined via prescription records. The association of OAA and 
      chronic medication PDCs will be quantified via correlation and chi-squared tests. 
      The association between symptom experience and OAA adherence will be examined via 
      correlation analyses. For implementation, characteristics of patient 
      participants, feasibility, acceptability, adoption, fidelity, and trialability 
      will be described. Data will be collected via EMR and pharmacist and patient 
      interviews. Median/IQR for acceptability, adoption and fidelity will be reported, 
      and patient interviews will be analyzed using a grounded theory approach and 
      pharmacist interviews will be analyzed using thematic analyses.
CI  - (c) 2022 The Authors. Published by Elsevier Inc.
FAU - Farris, Karen B
AU  - Farris KB
AD  - University of Michigan College of Pharmacy, 428 Church Street, Ann Arbor, MI 
      48103, United States of America.
FAU - Cadwallader, Tiffany
AU  - Cadwallader T
AD  - Auburn University Harrison School of Pharmacy, Walker Bldg, 2315, Auburn, AL 
      36849, United States of America.
FAU - Farley, Joel
AU  - Farley J
AD  - University of Minnesota College of Pharmacy, 308 SE Harvard St, Minneapolis, MI 
      55455, United States of America.
FAU - Gatwood, Katie
AU  - Gatwood K
AD  - Vanderbilt University Medical Center, Department of Pharmacy, 1211 Medical Center 
      Drive, Nashville, TN 37232, United States of America.
FAU - Mackler, Emily
AU  - Mackler E
AD  - University of Michigan, POEM (Pharmacists Optimizing Oncology Care Excellence in 
      Michigan), 2500 Green Road, Suite 100, Ann Arbor, MI 48105, United States of 
      America.
FAU - Gatwood, Justin
AU  - Gatwood J
AD  - University of Tennessee Health Science Center College of Pharmacy, 302 S 
      Perimeter Park Dr, Nashville, TN 37211, United States of America.
LA  - eng
PT  - Journal Article
DEP - 20220729
PL  - United States
TA  - Explor Res Clin Soc Pharm
JT  - Exploratory research in clinical and social pharmacy
JID - 9918266300706676
PMC - PMC9358049
OTO - NOTNLM
OT  - Multiple chronic conditions
OT  - Oral anticancer agents
OT  - Pharmacists coordinated care oncology model
EDAT- 2022/08/13 06:00
MHDA- 2022/08/13 06:01
PMCR- 2022/07/29
CRDT- 2022/08/12 02:44
PHST- 2021/11/19 00:00 [received]
PHST- 2022/06/21 00:00 [revised]
PHST- 2022/07/26 00:00 [accepted]
PHST- 2022/08/12 02:44 [entrez]
PHST- 2022/08/13 06:00 [pubmed]
PHST- 2022/08/13 06:01 [medline]
PHST- 2022/07/29 00:00 [pmc-release]
AID - S2667-2766(22)00062-2 [pii]
AID - 100163 [pii]
AID - 10.1016/j.rcsop.2022.100163 [doi]
PST - epublish
SO  - Explor Res Clin Soc Pharm. 2022 Jul 29;7:100163. doi: 
      10.1016/j.rcsop.2022.100163. eCollection 2022 Sep.